Bionano Genomics, Inc.
BNGOBionano Genomics, Inc. in brief
Bionano Genomics, Inc. is a listed company in the Diagnostics and Research industry, based in San Diego, California, USA. It was founded in 2003. Its market value was $17 M on 30 October 2026, which makes it the 24,827th largest listed company in the world and the 4,191st largest in the USA on this site. In the year to December 2025 it had sales of $29 M and a net loss of $26 M. It employs about 299 people and R. Erik Holmlin is its chief executive. Its largest product and service lines by sales in 2025 were Consumables (49%), Software (22%) and Instruments (22%). By market, the largest shares of its 2025 sales came from EMEA (49%), Americas (43%) and Asia Pacific (8%). Its shares trade under the symbol BNGO (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Bionano Genomics, Inc.
Bionano Genomics is a Developing Innovative Solutions company in the life sciences and health care industries. The company annual revenue is 8.5 million USD and 147 employees as on 2020. The headquarters is in USA.
Bionano Genomics, Inc. timeline
- 2003
- 🏁· approximateFounded
- 2007
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2011
- ✎Renamed BioNano Genomics, IncFormerly BioNanomatrix Inc.
- 2018
- 🔔Initial public offering on Nasdaq as BNGOFinal prospectus filed with the SEC on 22 August 2018; shares registered for exchange trading on 17 August 2018.
- 2023
- 💰Record revenue of $36 millionFY2023, the highest of the 8 years on record.
Events of Bionano Genomics, Inc. from Wikidata, SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #4,302 (Jan 2020) · #2,797 (Jan 2021) · #2,763 (Jan 2022) · #2,705 (Dec 2022) · #3,689 (Jul 2023) · #3,895 (Jan 2024) · #2,370 (Mar 2026) · #3,998 (Aug 2026) · #4,113 (Oct 2026) · #4,193 (Oct 2026)
Key ratios
- P/E ratio (TTM)
- n/m (loss)
- Price / sales (TTM)
- 0.5×
- Price / book
- 0.4×
- Free cash flow yield
- -228.2%
- Net margin (TTM)
- -96.8%
- Operating margin
- -116.9%
- Return on equity
- -67.8%
- Liabilities / assets
- 39.6%
- Net debt
- $-25M
- Revenue growth
- -7.4%
- R&D / revenue
- 39.9%
- Revenue per employee
- $95 K
- Profit per employee
- $-88 K
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $29M | -7.4% | $-33M | $-26M | -92.6% |
| Dec 2024 | $31M | -14.8% | $-104M | $-112M | -363.9% |
| Dec 2023 | $36M | +29.9% | $-215M | $-232M | -643.7% |
| Dec 2022 | $28M | +54.6% | $-132M | $-133M | -477.0% |
| Dec 2021 | $18M | +111.5% | $-77M | $-72M | -402.9% |
| Dec 2020 | $9M | -16.1% | $-39M | $-41M | -483.6% |
| Dec 2019 | $10M | -15.6% | $-26M | $-30M | -294.4% |
| Dec 2018 | $12M | — | $-20M | $-19M | -154.2% |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $-16M | — | — | $-4.85 | — |
| Dec 2024 | $-69M | — | — | $-88.13 | — |
| Dec 2023 | $-125M | — | — | $-408.60 | — |
| Dec 2022 | $-125M | — | — | $-4.58 | — |
| Dec 2021 | $-72M | — | — | $-0.26 | — |
| Dec 2020 | $-38M | $0M | $-38M | $-0.39 | — |
| Dec 2019 | $-30M | $0M | $-30M | $-1.99 | — |
| Dec 2018 | $-20M | $0M | $-20M | $-2.61 | — |
Quarterly results
Latest quarter to Sep 2026: revenue $8M (+12.3% on a year earlier), net income $-6M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.
SEC filings
- Nov 10, 202610-QQuarterly report · period to Sep 2026
- Nov 10, 20268-KCurrent reportResults of operations
- Oct 27, 2026S-1IPO registration
- Sep 14, 20268-KCurrent reportRegulation FD disclosure
- Aug 10, 202610-QQuarterly report · period to Jun 2026
- Aug 10, 20268-KCurrent reportResults of operations
- Jun 24, 20268-KCurrent reportOther events
- Jun 5, 20268-KCurrent reportDirectors or officers changed
- May 28, 20268-KCurrent reportOther events
- May 14, 20268-KCurrent reportShareholder vote
- May 13, 202610-QQuarterly report · period to Mar 2026
- May 13, 20268-KCurrent reportResults of operations
Official filings of Bionano Genomics, Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- $29 M
- Operating income
- $-33 M
- Net income
- $-26 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $74 M
- Total liabilities
- $29 M
- Total equity
- $44 M
As of December-2025
Top 36 institutional investors in Bionano Genomics, Inc.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | AIGH Capital Management LLC | 1,165,000 | New | 8.33% | $2 M | Nov 2, 2026 |
| 2 | Two Sigma Investments, LP | 483,557 | New | 3.46% | $1 M | Nov 16, 2026 |
| 3 | Renaissance Technologies LLC | 154,000 | +102,900 (+201.37%) | 1.10% | $0 M | Nov 12, 2026 |
| 4 | Vanguard Capital Management LLC | 138,786 | +56,398 (+68.45%) | 0.99% | $0 M | Nov 13, 2026 |
| 5 | Carret Asset Management, LLC | 135,545 | +10,545 (+8.44%) | 0.97% | $0 M | Nov 4, 2026 |
| 6 | HRT Financial LP | 96,866 | +85,126 (+725.09%) | 0.69% | $0 M | Nov 13, 2026 |
| 7 | Gsa Capital Partners LLP | 92,384 | -57,900 (-38.53%) | 0.66% | $0 M | Nov 16, 2026 |
| 8 | Acadian Asset Management LLC | 89,186 | New | 0.64% | $0 M | Nov 9, 2026 |
| 9 | Jane Street Group, LLC | 86,321 | +50,593 (+141.61%) | 0.62% | $0 M | Nov 12, 2026 |
| 10 | Geode Capital Management, LLC | 77,274 | -12,719 (-14.13%) | 0.55% | $0 M | Nov 6, 2026 |
| 11 | Vanguard Fiduciary Trust Co | 51,578 | 0 (0.00%) | 0.37% | $0 M | Nov 13, 2026 |
| 12 | Prudential Financial Inc | 33,000 | +1,400 (+4.43%) | 0.24% | $0 M | Nov 16, 2026 |
| 13 | Northern Trust Corp | 24,559 | -2 (-0.01%) | 0.18% | $0 M | Nov 16, 2026 |
| 14 | UBS Group AG | 14,168 | +13,356 (+1644.83%) | 0.10% | $0 M | Nov 10, 2026 |
| 15 | Engineers Gate Manager LP | 11,830 | -158 (-1.32%) | 0.08% | $0 M | Nov 16, 2026 |
| 16 | Citadel Advisors LLC | 10,905 | New | 0.08% | $0 M | Nov 16, 2026 |
| 17 | Warberg Asset Management LLC | 10,000 | New | 0.07% | $0 M | Nov 2, 2026 |
| 18 | BlackRock, Inc. | 9,937 | 0 (0.00%) | 0.07% | $0 M | Nov 13, 2026 |
| 19 | Osaic Holdings, Inc. | 6,783 | -1,026 (-13.14%) | 0.05% | $0 M | Nov 12, 2026 |
| 20 | Tower Research Capital LLC (TRC) | 2,989 | -2,239 (-42.83%) | 0.02% | $0 M | Nov 16, 2026 |
| 21 | Bolton Securities Corporation | 1,004 | 0 (0.00%) | 0.01% | $0 M | Nov 12, 2026 |
| 22 | Group One Trading LLC | 957 | 0 (0.00%) | 0.01% | $0 M | Nov 10, 2026 |
| 23 | Morgan Stanley | 782 | -255 (-24.59%) | 0.01% | $0 M | Nov 13, 2026 |
| 24 | National Bank Of Canada /fi/ | 313 | +311 (+15550.00%) | 0.00% | $0 M | Nov 16, 2026 |
| 25 | SBI Securities Co., Ltd. | 273 | +27 (+10.98%) | 0.00% | $0 M | Oct 22, 2026 |
Show all 36: investors 26 to 36
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 26 | Wells Fargo & Company/mn | 113 | 0 (0.00%) | 0.00% | $0 M | Nov 16, 2026 |
| 27 | BNP Paribas Financial Markets | 13 | 0 (0.00%) | 0.00% | $0 M | Nov 12, 2026 |
| 28 | Jpmorgan Chase & Co | 11 | 0 (0.00%) | 0.00% | $0 M | Nov 12, 2026 |
| 29 | Royal Bank Of Canada | 11 | 0 (0.00%) | 0.00% | $0 M | Nov 16, 2026 |
| 30 | Allworth Financial LP | 6 | New | 0.00% | $0 M | Nov 17, 2026 |
| 31 | TD Waterhouse Canada Inc. | 5 | 0 (0.00%) | 0.00% | $0 M | Oct 16, 2026 |
| 32 | Activest Wealth Management | 3 | 0 (0.00%) | 0.00% | $0 M | Oct 15, 2026 |
| 33 | Barclays PLC | 2 | -1 (-33.33%) | 0.00% | $0 M | Nov 6, 2026 |
| 34 | Atlantic Union Bankshares Corp | 1 | 0 (0.00%) | 0.00% | $0 M | Nov 12, 2026 |
| 35 | Robinhood Markets, Inc. | 1 | — | 0.00% | $0 M | Nov 18, 2026 |
| 36 | Medallion Wealth Advisors, LLC | 1 | 0 (0.00%) | 0.00% | $0 M | Nov 13, 2026 |
Mutual funds holding Bionano Genomics, Inc.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC | 113,564 | $0 M | 0.81% | <0.01% | +119% | May 31, 2026 |
| 🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc. | 82,388 | $0 M | 0.59% | <0.01% | +21% | Jun 30, 2026 |
| 🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC | 11,470 | $0 M | 0.08% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC | 2,769 | $0 M | 0.02% | <0.01% | no change | May 31, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jun 30, 2026. The 4 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at Bionano Genomics, Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Albert LudererInterim Chief Executive, Director | Buyindirect | +4,000 | $1.210 | $5 K | 8,000 | Form 4 |
| filed | Albert LudererInterim Chief Executive, Director | Buyindirect | +4,000 | $1.220 | $5 K | 4,000 | Form 4 |
| filed | Mark OldakowskiCHIEF OPERATING OFFICER | Shares withheld for tax | -27 | $1.300 | $35 | 868 | Form 4 |
| filed | Jonathan V. DixonGENERAL COUNSEL | Shares withheld for tax | -24 | $1.300 | $31 | 239 | Form 4 |
| filed | Mark AdamchakPrincipal Accounting Officer | Shares withheld for tax | -7 | $1.300 | $9 | 253 | Form 4 |
| filed | Alka ChaubeyCHIEF MEDICAL OFFICER | Shares withheld for tax | -24 | $1.300 | $31 | 620 | Form 4 |
| filed | Mark AdamchakPrincipal Accounting Officer | Shares withheld for tax | -3 | $1.100 | $3 | 260 | Form 4 |
| filed | Jonathan V. DixonGENERAL COUNSEL | Shares withheld for tax | -6 | $1.100 | $7 | 263 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: Bionano Genomics, Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Stock splits: 1-for-60.24 reverse split ; 1-for-10 reverse split ; 1-for-2 reverse split ; 1-for-21.41 reverse split
Trading halts
- 2025-01-25 00:50 UTC, code T3, resumed 14:00 UTC
Fails to deliver
- : 708 shares at $1.20
- : 790 shares at $1.16
- : 1,007 shares at $1.46
- : 645 shares at $1.45
- : 744 shares at $1.48
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Bionano Genomics, Inc. scorecard#
Passes 5 of the 19 checks that could be worked out: strongest in valuation (2 of 4), weakest in growth (1 of 6). Fiscal year 2025; market cap of Oct 30, 2026.
Valuation2 of 4
- ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
- ✓Price to book below its peers' median0.4×Price to book 0.4× against Diagnostics and Research's median of 3.7×.
- ✓Price to sales below its peers' median0.5×Price to sales 0.5× against Diagnostics and Research's median of 4.5×.
- –Free cash flow yield above 5%No free cash flow yield on file.
- ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
- –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
Growth1 of 6
- ✗Revenue grew in the newest year-7.4%Revenue down 7.4% in fiscal 2025.
- ✗Revenue up more than 5% a year over three years0.8%0.8% a year over the three years to fiscal 2025.
- ✗Faster growth over three years than its peers' median0.8%0.8% a year against Diagnostics and Research's median of 3.6% (64 companies).
- ✗Earnings per share grew in the newest year-4.85 vs -88.13Diluted EPS -4.85 in fiscal 2025 against -88.13 the year before (report's currency).
- ✓Net income higher than five years earlier-$26 M-$26 M in fiscal 2025 against -$41 M in 2020.
- ✗Revenue rose in at least four of the last five years3 of 5Revenue rose in 3 of the five years to fiscal 2025.
Profitability1 of 5
- ✗Profitable in the newest year-$26 MNet income -$26 M in fiscal 2025.
- ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
- ✗Operating margin above its peers' median-116.9%-116.9% against Diagnostics and Research's median of -2.4% (66 companies).
- ✗Return on equity above 15%-66.2%-66.2% in fiscal 2025.
- –Return on invested capital above 10%No return on invested capital on file.
- ✓Operating margin wider than three years earlier-116.9%-116.9% in fiscal 2025 against -473.7% in 2022.
Financial health1 of 3
- ✓Short-term assets cover short-term liabilities2.0×Current ratio 1.98 at the end of fiscal 2025.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
- ✗Altman Z-score outside the distress zone-14.09Z-score -14.09 (distress zone) for fiscal 2025.
Shareholder returns0 of 1
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✗Share count up no more than 2% in a year328.4%Diluted shares up 328.4% in fiscal 2025.
- –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
- –Free cash flow covers dividends and buybacksCash from operations or capital spending is not on file.
Worked out from the statements as filed (sec), the medians of Diagnostics and Research, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Financial analysis, 2025#
Worked out from Bionano Genomics, Inc.'s statements, beside the median of Diagnostics and Research.
| Ratio | Trend | 2025 | Median of peers |
|---|---|---|---|
| Operating margin | -116.9% | -2.4% | |
| Net margin | -92.6% | -3.6% | |
| Return on equity | -66.2% | -5.4% | |
| Revenue growth, 3 years a year | 0.8% | 3.6% | |
| Revenue growth | -7.4% | 6.6% |
4of 8on the Piotroski tests of financial strength
- Revenue fell 7.4% against the year before.
- Net loss of $26 million, the 9th loss-making year in a row.
- The share count rose 328.4% in the year.
Bionano Genomics, Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 | FY 2019to Dec 31, 2019 | FY 2018to Dec 31, 2018 | FY 2017to Dec 31, 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | 29−7.4%100% | 31−14.8%100% | 36+29.9%100% | 28+54.6%100% | 18+111%100% | 8.5r8.5−16.1%100% | 10−15.6%100% | 12+26.3%100% | 9.5—100% | |
| Cost of revenue | 15−49.6%53.7% | 30+14.5%98.8% | 27+21.5%73.5% | 22+54.9%78.6% | 14+146%78.5% | 5.7r5.7−15.3%67.4% | 6.8−22.3%66.8% | 8.7+44.5%72.6% | 6.0—63.4% | |
| Research and development | 11−54.1%39.9% | 25−54.1%80.6% | 54+10.2%150% | 49+118%176% | 22+119%125% | 10r10+12.9%121% | 9.1−4.3%89.6% | 9.5−21.0%79.0% | 12—126% | |
| Selling, general and administrative | 35−32.2%123% | 52−44.1%168% | 93r93+4.7%257% | 89+51.5%319% | 58+88.3%325% | 31r31+54.1%365% | 20+41.7%199% | 14+1.0%118% | 14—148% | |
| Total costs and expenses | 47−55.4%163% | 104−53.6%339% | 225+63.3%622% | 138+70.0%495% | 81+96.0%450% | 41r41+41.3%486% | 29+23.3%289% | 24−11.2%198% | 27—281% | |
| Operating income | −33—−117% | −104—−338% | −215—−596% | −132—−474% | −77—−429% | −39r−39—−453% | −26—−255% | −20—−170% | −23—−244% | |
| Interest and finance income | 1.0−33.3%3.5% | 1.5−54.5%4.9% | 3.3+120%9.1% | 1.5+275%5.4% | 0.4—2.2% | — | — | — | — | |
| Interest expense and finance costs | — | — | 5.1+1618%14.2% | 0.3−67.9%1.1% | 0.9−63.2%5.2% | 2.5r2.5+10.2%29.6% | 2.3+65.5%22.6% | 1.4+134%11.5% | 0.6—6.2% | |
| Other non-operating income (expense) | 7.0—24.6% | −8.0—−26.0% | −17−1843%−47.6% | 1.0—3.5% | −1.1—−5.8% | −2.5r−2.5—−29.7% | −3.9−303%−38.7% | 1.9—16.1% | −0.1—−1.3% | |
| Income before tax | −26—−92.4% | −112—−364% | −232—−644% | −131—−470% | −78—−435% | −41r−41—−483% | −30—−294% | −18—−154% | −23—−246% | |
| Income tax | 0.1+103%0.2% | 0.0−46.8%0.1% | 0.1−96.7%0.2% | 1.9—6.8% | −5.7−19814%−31.8% | 0.0r0.0+37.8%0.3% | 0.0+35.7%0.2% | 0.0−16.4%0.1% | 0.0—0.2% | |
| Net income including minority interests | — | — | — | −133—−477% | −72—−403% | −41r−41—−483% | −30—−294% | −18—−154% | −23—−246% | |
| Net income attributable to shareholders | −26—−92.6% | −112—−364% | −232—−644% | −133—−477% | −72—−403% | −41r−41—−483% | −30—−294% | −18—−154% | −23—−246% | |
| Earnings per share, basic | -4.85—— | -88.13—— | -408.60r-6.81—— | -4.58r-0.46—— | -0.26—— | -0.39—— | -1.99—— | -2.61—— | -8.65—— | |
| Earnings per share, diluted | -4.85—— | -88.13—— | -408.60r-6.81—— | -4.58r-0.46—— | -0.26—— | -0.39—— | -1.99—— | -2.61—— | -8.65—— | |
| Shares, weighted average (basic) | 5.4+328%— | 1.3+123%— | 0.6r34−98.0%— | 29r289−89.6%— | 277—— | — | — | — | — | |
| Shares, weighted average (diluted) | 5.4+328%— | 1.3+123%— | 0.6r34−98.0%— | 29r289−89.6%— | 277+165%— | 104r104+596%— | 15+112%— | 7.1+162%— | 2.7—— | |
| Balance sheet | ||||||||||
| Cash and cash equivalents | 3.0−67.4%4.1% | 9.2−48.9%12.0% | 18+253%8.4% | 5.1−79.3%1.7% | 25−36.1%6.5% | 38r38+122%63.6% | 17r17+4.8%57.3% | 17+1517%66.6% | 1.0—10.1% | |
| Short-term investments | 16+5290%22.1% | 0.3−99.4%0.4% | 49−54.8%22.8% | 108−52.2%35.2% | 226—59.9% | 0—0.0% | — | — | — | |
| Receivables | 5.2+9.4%7.1% | 4.8−49.0%6.2% | 9.3+32.7%4.3% | 7.0+42.3%2.3% | 4.9+77.8%1.3% | 2.8r2.8−56.2%4.6% | 6.3r6.3+40.3%21.0% | 4.5+34.7%18.2% | 3.4—33.0% | |
| Inventory | 7.8−41.0%10.6% | 13−51.9%17.3% | 28−7.3%12.9% | 30+140%9.7% | 12+274%3.3% | 3.3r3.3−3.7%5.5% | 3.4r3.4+222%11.4% | 1.1−36.9%4.3% | 1.7—16.7% | |
| Other current assets | 1.8+33.5%2.4% | 1.3r1.3+35.0%1.7% | 1.0r1.0−59.5%0.5% | 2.4r2.4+75.0%0.8% | 1.4r2.3+198%0.4% | 0.5r0.5+1.1%0.8% | 0.5r0.5+19.0%1.5% | 0.4−30.2%1.5% | 0.6r0.6—5.4% | |
| Current assets | 45+14.9%61.7% | 39−71.8%51.5% | 140−10.9%65.4% | 157−42.3%51.2% | 272+482%72.2% | 47r47+65.6%77.4% | 28r28+22.7%93.5% | 23+223%92.8% | 7.1—70.4% | |
| Property, plant and equipment | 15−22.7%20.2% | 19−17.7%25.1% | 23+29.5%10.9% | 18+74.7%5.9% | 10+110%2.7% | 4.9r4.9+152%8.1% | 1.9r1.9+9.7%6.5% | 1.8−40.9%7.2% | 3.0—29.6% | |
| Right-of-use (leased) assets | 3.2+78.3%4.4% | 1.8−68.0%2.4% | 5.6−22.0%2.6% | 7.2+7.9%2.3% | 6.7—1.8% | 0—0.0% | — | — | — | |
| Goodwill | — | — | 0−100%0.0% | 77+37.6%25.1% | 56+683%14.9% | 7.2r7.2—11.9% | 0—0.0% | — | — | |
| Other intangible assets | 4.3−55.2%5.9% | 9.7−71.4%12.7% | 34−17.4%15.8% | 41+53.3%13.4% | 27+1720%7.1% | 1.5r1.5—2.4% | 0—0.0% | — | — | |
| Total assets | 74−4.0%100% | 77−64.2%100% | 214−30.3%100% | 308−18.5%100% | 377+524%100% | 60r60+100%100% | 30r30+21.8%100% | 25+144%100% | 10—100% | |
| Accounts payable | 5.6−19.7%7.6% | 7.0−33.0%9.1% | 10−17.2%4.8% | 13+16.4%4.1% | 11r9.7+268%2.9% | 2.9r2.9+8.6%4.8% | 2.7r2.7+99.7%8.9% | 1.4−41.3%5.5% | 2.3—22.7% | |
| Debt due within a year | — | — | — | — | — | 0−100%0.0% | 20r20—66.5% | 0−100%0.0% | 6.7—66.3% | |
| Current liabilities | 23−38.6%31.2% | 37−62.7%48.7% | 100+179%46.7% | 36+64.3%11.7% | 22+144%5.8% | 8.9r8.9−66.1%14.8% | 26r26+483%87.3% | 4.5−72.8%18.2% | 17—164% | |
| Long-term debt | — | — | — | — | 0−100%0.0% | 16r16—27.0% | 0−100%0.0% | 9.0—36.4% | 0—0.0% | |
| Lease liabilities (non-current) | 2.5+1617%3.4% | 0.1−96.0%0.2% | 3.6−34.8%1.7% | 5.5+4.1%1.8% | 5.3—1.4% | 0—0.0% | — | — | — | |
| Total liabilities | 29−29.4%39.6% | 41−65.1%53.9% | 118+104%55.2% | 58+45.3%18.9% | 40+57.6%10.6% | 25r25−4.6%42.0% | 27r27+81.3%88.0% | 15−15.5%59.1% | 17—171% | |
| Retained earnings | −720—−978% | −693—−904% | −581—−271% | −349—−113% | −216—−57.3% | −144r−144—−238% | −103r−103—−340% | −73—−293% | −54—−535% | |
| Shareholders' equity | 44+25.6%60.4% | 35−63.2%46.1% | 96−61.4%44.8% | 249r249−26.0%81.1% | 337+861%89.4% | 35r35+871%58.0% | 3.6r3.6−64.4%12.0% | 10r10—40.9% | −50—−495% | |
| Total liabilities and equity | 74−4.0%100% | 77−64.2%100% | 214−30.3%100% | 308−18.5%100% | 377+524%100% | 60r60+100%100% | 30r30+21.8%100% | 25+144%100% | 10—100% | |
| Shares outstanding | 11+476%— | 1.9+145%— | 0.8r46−97.4%— | 30r297−89.7%— | 290+52.5%— | 190r190+454%— | 34r34+241%— | 10+12915%— | 0.1—— | |
| Cash-flow statement | ||||||||||
| Depreciation and amortization | 9.5−32.1%33.4% | 14+2.3%45.6% | 14+42.5%38.0% | 9.6+187%34.6% | 3.4+127%18.6% | 1.5r1.5+31.1%17.4% | 1.1−14.6%11.1% | 1.3−12.2%11.0% | 1.5—15.8% | |
| Share-based compensation | 4.5−53.4%15.9% | 9.7−35.9%31.6% | 15−32.3%42.0% | 22+131%80.6% | 9.7+525%54.1% | 1.6r1.6+15.5%18.3% | 1.3+12.7%13.3% | 1.2+212%9.9% | 0.4—4.0% | |
| Cash from operating activities | −16—−57.3% | −69—−224% | −125—−347% | −125—−449% | −72—−400% | −38r−38—−451% | −30—−292% | −20—−166% | −21—−219% | |
| Capital expenditure | — | — | — | — | — | 0—0.0% | −0.1—−0.6% | −0.3—−2.8% | −1.0—−10.7% | |
| Intangible assets bought | — | — | 0—0.0% | −0.1—−0.4% | 0—0.0% | — | — | — | — | |
| Acquisitions, net of cash acquired | — | — | 0—0.0% | −31—−113% | — | −2.4—−28.8% | 0—0.0% | — | — | |
| Cash from investing activities | −13−117%−44.7% | 74+206%240% | 24−70.8%66.9% | 83—298% | −278—−1546% | −2.5r−2.4—−28.8% | −0.1—−0.6% | −0.3—−2.8% | −1.0—−10.7% | |
| Shares issued | 31−30.0%109% | 44−23.0%144% | 58+149%160% | 23—83.2% | — | — | — | — | — | |
| Cash from financing activities | 24—84.3% | −14−112%−44.5% | 114+395%315% | 23−93.2%82.8% | 336+443%1869% | 62r62+104%728% | 30−15.1%300% | 36+103%298% | 18—185% | |
| Exchange-rate effect on cash | −0.0—−0.0% | −0.0−111%−0.0% | 0.1—0.2% | −0.0—−0.1% | 0—0.0% | — | — | — | — | |
| Change in cash | −5.1—−17.8% | −8.8−168%−28.5% | 13—35.6% | −19—−68.6% | −14−166%−77.2% | 21r21+2580%249% | 0.8−94.9%7.8% | 16—129% | −4.2—−44.5% | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Sep 30, 2026 | Q3 FY2026to Sep 30, 2026 | Q2 FY2026to Jun 30, 2026 | Q1 FY2026to Mar 31, 2026 | Q4 FY2025to Dec 31, 2025 | Q3 FY2025to Sep 30, 2025 | Q2 FY2025to Jun 30, 2025 | Q1 FY2025to Mar 31, 2025 | Q4 FY2024to Dec 31, 2024 | Q3 FY2024to Sep 30, 2024 | Q2 FY2024to Jun 30, 2024 | Q1 FY2024to Mar 31, 2024 | Q4 FY2023to Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Revenue | 31+8.2%100% | 8.3+12.3%100% | 8.2+21.4%100% | 6.7+3.6%100% | 8.0*−2.6%100% | 7.4+21.3%100% | 6.7−13.4%100% | 6.5−26.4%100% | 8.2*−23.9%100% | 6.1—100% | 7.8—100% | 8.8—100% | 11*—100% | |
| Cost of revenue | 16+4.2%52.0% | 4.3+8.3%52.3% | 3.9+18.5%47.2% | 3.4−2.4%51.4% | 4.6*−4.1%57.3% | 4.0−72.5%54.3% | 3.3−37.2%48.4% | 3.5−40.8%54.5% | 4.7*−42.7%58.1% | 15—239% | 5.2—66.7% | 5.9—67.8% | 8.3*—77.3% | |
| Research and development | 12+6.7%39.9% | 3.0+7.0%36.8% | 3.0+1.9%36.6% | 3.1+32.4%46.9% | 3.2*−7.1%40.6% | 2.8−39.7%38.6% | 2.9−57.1%43.5% | 2.4−75.8%36.7% | 3.5*−70.3%42.6% | 4.7—77.7% | 6.8—87.9% | 9.8—112% | 12*—109% | |
| Selling, general and administrative | 33−14.4%105% | 7.4−17.9%89.9% | 8.5+2.4%105% | 8.0−11.3%120% | 8.7*−25.9%109% | 9.1−4.2%123% | 8.3−27.8%124% | 9.0−52.7%140% | 12*−21.4%144% | 9.5—156% | 12—149% | 19r20—218% | 15r16*—139% | |
| Total costs and expenses | 45−9.7%145% | 10−11.9%127% | 12+2.3%141% | 11−2.2%167% | 12*−22.3%150% | 12−66.4%162% | 11−42.5%167% | 11−66.4%177% | 15*−43.9%188% | 35—584% | 20—252% | 34—387% | 27*—255% | |
| Operating income | −30—−97.1% | −6.5—−79.0% | −7.2—−88.3% | −7.9—−118% | −8.5*—−107% | −8.5—−116% | −7.8—−116% | −8.5—−131% | −12*—−146% | −44—−723% | −17—−219% | −31—−355% | −25*—−233% | |
| Interest expense and finance costs | — | — | — | — | — | — | — | — | — | — | — | 0.1—1.4% | 4.9*—45.7% | |
| Other non-operating income (expense) | 0.1—0.4% | 0.1+85.7%1.1% | −0.2−121%−2.4% | −0.4−107%−5.9% | 0.6*—8.0% | 0.0—0.7% | 1.0+16.2%14.2% | 5.4—83.2% | −8.2*—−100% | −0.3—−5.3% | 0.8—10.6% | −0.3—−3.6% | −19*—−177% | |
| Income before tax | −30—−96.7% | −6.4—−77.9% | −7.4—−90.8% | −8.3—−124% | −7.9*—−99.3% | −8.5—−115% | −6.8—−102% | −3.1—−47.9% | −20*—−247% | −44—−728% | −16—−208% | −31—−359% | −44*—−410% | |
| Income tax | 0.1+87.5%0.2% | 0.0−42.9%0.1% | 0.0−30.0%0.1% | 0.0+42.9%0.1% | 0.0*+3400%0.4% | 0.0−41.7%0.2% | 0.0−61.5%0.1% | 0.0—0.1% | 0.0*—0.0% | 0.0—0.4% | 0.0—0.3% | −0.0—−0.2% | −0.0*—−0.3% | |
| Net income attributable to shareholders | −30—−96.9% | −6.5—−78.0% | −7.4—−90.8% | −8.3—−124% | −7.9*—−99.8% | −8.5—−115% | −6.9—−102% | −3.1—−48.0% | −20*—−247% | −44—−729% | −16—−209% | −31—−358% | −44*—−409% | |
| Earnings per share, basic | — | -0.54—— | -0.64—— | -0.76—— | — | -1.59—— | -1.99—— | -1.15—— | — | -30.92r-0.52—— | -14.41r-0.24—— | -35.75r-0.60—— | — | |
| Earnings per share, diluted | — | -0.54—— | -0.64—— | -0.76—— | — | -1.59—— | -1.99—— | -1.15—— | — | -30.92r-0.52—— | -14.41r-0.24—— | -35.75r-0.60—— | — | |
| Shares, weighted average (basic) | 12+125%— | 12+125%— | 12+236%— | 11+308%— | — | 5.3+273%— | 3.4+206%— | 2.7+206%— | — | 1.4r86—— | 1.1r68—— | 0.9r53—— | — | |
| Shares, weighted average (diluted) | 12+125%— | 12+125%— | 12+236%— | 11+308%— | — | 5.3+273%— | 3.4+206%— | 2.7+206%— | — | 1.4r86—— | 1.1r68—— | 0.9r53—— | — | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 4.4—9.4% | 4.4+42.1%9.4% | 3.7+4.7%7.8% | 3.4−5.5%5.3% | 3.0−67.4%4.1% | 3.1−65.1%3.9% | 3.6−65.8%4.7% | 3.6−77.0%4.6% | 9.2−48.9%12.0% | 8.8—10.1% | 10—8.1% | 16—10.0% | 18—8.4% | |
| Short-term investments | 3.8—8.2% | 3.8−79.4%8.2% | 6.2−51.9%13.0% | 11−24.8%16.9% | 16+5290%22.1% | 19+486%23.4% | 13+51.2%16.9% | 15+16.3%18.6% | 0.3−99.4%0.4% | 3.2—3.6% | 8.5—6.6% | 13—8.0% | 49—22.8% | |
| Receivables | 5.9—12.6% | 5.9+29.3%12.6% | 4.4+25.0%9.2% | 4.1+23.2%6.4% | 5.2+9.4%7.1% | 4.5−14.9%5.7% | 3.5−44.2%4.6% | 3.4−59.7%4.3% | 4.8−49.0%6.2% | 5.3—6.1% | 6.3—4.8% | 8.3—5.3% | 9.3—4.3% | |
| Inventory | 8.7—18.8% | 8.7+3.3%18.8% | 7.0−31.9%14.7% | 7.7−32.7%11.9% | 7.8−41.0%10.6% | 8.4−48.3%10.7% | 10−55.5%13.6% | 11−52.0%14.6% | 13−51.9%17.3% | 16—18.6% | 23—17.9% | 24—15.1% | 28—12.9% | |
| Other current assets | 4.5—9.7% | 4.5−16.6%9.7% | 4.9+57.8%10.3% | 4.9+74.8%7.5% | 1.8+33.5%2.4% | 5.4+22.6%6.8% | 3.1−36.6%4.1% | 2.8−43.7%3.5% | 1.3r1.3+35.0%1.7% | 4.4—5.0% | 4.9—3.8% | 4.9—3.1% | 1.0r1.0—0.5% | |
| Current assets | 26—55.1% | 26−47.7%55.1% | 25−41.7%52.3% | 39−13.3%60.1% | 45+14.9%61.7% | 49+3.9%61.7% | 43−29.6%56.1% | 45−47.5%57.3% | 39−71.8%51.5% | 47—53.8% | 61—46.8% | 86—54.2% | 140—65.4% | |
| Property, plant and equipment | 12—26.4% | 12−24.4%26.4% | 13−24.6%27.4% | 14−23.4%21.7% | 15−22.7%20.2% | 16−19.1%20.5% | 17−30.6%22.7% | 18−27.5%23.4% | 19−17.7%25.1% | 20—22.9% | 25—19.2% | 25—16.0% | 23—10.9% | |
| Right-of-use (leased) assets | 2.8—6.1% | 2.8−19.8%6.1% | 2.9−22.2%6.2% | 3.1+176%4.7% | 3.2+78.3%4.4% | 3.5+23.4%4.4% | 3.8−10.6%5.0% | 1.1−77.2%1.4% | 1.8−68.0%2.4% | 2.8—3.2% | 4.2—3.3% | 4.9—3.1% | 5.6—2.6% | |
| Goodwill | — | — | — | — | — | — | — | — | — | — | — | — | 0—0.0% | |
| Other intangible assets | 0.3—0.7% | 0.3−94.3%0.7% | 1.7−76.3%3.5% | 3.0−64.1%4.6% | 4.3−55.2%5.9% | 5.7−48.5%7.2% | 7.0−76.6%9.2% | 8.4−73.6%10.7% | 9.7−71.4%12.7% | 11—12.6% | 30—23.2% | 32—20.1% | 34—15.8% | |
| Total assets | 46—100% | 46−41.4%100% | 48−37.4%100% | 65−17.4%100% | 74−4.0%100% | 79−9.5%100% | 76−41.2%100% | 78−50.4%100% | 77−64.2%100% | 87—100% | 129—100% | 158—100% | 214—100% | |
| Accounts payable | 5.5—12.0% | 5.5−7.5%12.0% | 4.6−26.9%9.6% | 5.1−22.9%7.8% | 5.6−19.7%7.6% | 6.0−31.1%7.6% | 6.2−28.5%8.2% | 6.6−33.3%8.4% | 7.0−33.0%9.1% | 8.7—10.0% | 8.7—6.8% | 9.8—6.2% | 10—4.8% | |
| Current liabilities | 12—26.6% | 12−46.4%26.6% | 10−58.5%21.1% | 21−19.6%32.8% | 23−38.6%31.2% | 23−30.3%29.1% | 24−35.0%31.8% | 26−54.9%33.7% | 37−62.7%48.7% | 33—37.7% | 37—28.7% | 59—37.0% | 100—46.7% | |
| Lease liabilities (non-current) | 2.3—4.9% | 2.3−13.2%4.9% | 2.4−11.8%5.0% | 2.5—3.9% | 2.5+1617%3.4% | 2.6+50.2%3.3% | 2.7+20.6%3.6% | 0−100%0.0% | 0.1−96.0%0.2% | 1.7—2.0% | 2.2—1.7% | 2.8—1.7% | 3.6—1.7% | |
| Total liabilities | 18—39.1% | 18−38.2%39.1% | 16−47.8%33.6% | 27−9.5%42.2% | 29−29.4%39.6% | 29−24.0%37.0% | 31−37.5%40.3% | 30−59.8%38.5% | 41−65.1%53.9% | 38—44.1% | 49—37.9% | 75—47.6% | 118—55.2% | |
| Retained earnings | −742—−1602% | −742—−1602% | −735—−1545% | −728—−1123% | −720—−978% | −712—−900% | −703—−925% | −696—−888% | −693—−904% | −673—−770% | −629—−486% | −613—−388% | −581—−271% | |
| Shareholders' equity | 28—60.9% | 28−43.4%60.9% | 32−30.3%66.4% | 37−22.3%57.8% | 44+25.6%60.4% | 50+1.9%63.0% | 45−43.5%59.7% | 48−41.8%61.5% | 35−63.2%46.1% | 49r49—55.9% | 80r80—62.1% | 83r83—52.4% | 96—44.8% | |
| Total liabilities and equity | 46—100% | 46−41.4%100% | 48−37.4%100% | 65−17.4%100% | 74−4.0%100% | 79−9.5%100% | 76−41.2%100% | 78−50.4%100% | 77−64.2%100% | 87—100% | 129—100% | 158—100% | 214—100% | |
| Shares outstanding | 14—— | 14+38.8%— | 12+201%— | 11+264%— | 11+476%— | 9.7−89.0%— | 3.9−94.5%— | 3.1−94.6%— | 1.9+145%— | 88—— | 71—— | 58—— | 0.8r46—— | |
| Cash-flow statement | ||||||||||||||
| Depreciation and amortization | 9.2−3.7%29.7% | 2.3*−3.7%27.6% | 2.3*−3.5%28.1% | 2.3−5.1%34.5% | 2.3*−2.5%29.4% | 2.4*−57.8%32.3% | 2.4*−20.3%35.3% | 2.4−19.1%37.7% | 2.4*−33.3%29.4% | 5.6*—92.7% | 3.0*—38.5% | 3.0—34.3% | 3.6*—33.5% | |
| Share-based compensation | 2.9−48.3%9.2% | 0.3−68.2%3.6% | 1.0−10.2%11.9% | 0.7−57.8%10.0% | 0.9*−52.2%11.6% | 0.9−57.3%12.8% | 1.1−58.2%16.0% | 1.6−47.4%24.6% | 1.9*−42.6%23.7% | 2.2—36.3% | 2.6—33.2% | 3.0—34.4% | 3.4*—31.5% | |
| Cash from operating activities | −19—−61.4% | −4.5*—−54.7% | −4.7*—−57.2% | −5.7—−85.5% | −4.2*—−52.5% | −5.9*—−80.3% | −3.5*—−51.8% | −2.8—−42.8% | −6.5*—−79.7% | −13*—−219% | −21*—−270% | −28—−321% | −30*—−278% | |
| Cash from investing activities | 26—82.2% | 2.4*—29.1% | 14*+591%167% | 5.5—81.6% | 4.0*+33.8%50.4% | −4.7*—−63.4% | 2.0*−93.1%29.4% | −14−130%−218% | 3.0*—36.7% | −5.4*—−88.5% | 29*—368% | 48—543% | −55*—−516% | |
| Shares issued | 5.9−83.6%19.1% | 2.9*−77.9%34.5% | 0.6*−79.9%7.6% | 0.7−94.7%10.5% | 1.8*−73.9%22.0% | 13*+28.0%176% | 3.1*−74.6%45.9% | 13−13.8%206% | 6.7*−40.4%82.3% | 10*—166% | 12*—156% | 15—176% | 11*—105% | |
| Cash from financing activities | −4.7−118%−15.1% | 2.7*−72.8%33.1% | −9.7*−760%−119% | 0.7−94.0%9.8% | 1.6*−58.8%20.2% | 10*+67.3%137% | 1.5*—21.8% | 11—169% | 3.9*−94.3%47.7% | 6.0*—99.1% | −2.0*—−25.5% | −22—−247% | 68*—639% | |
| Exchange-rate effect on cash | 0.0—0.0% | 0.0*−93.3%0.0% | 0.0*—0.0% | 0.0—0.1% | 0.0*—0.1% | 0.0*−37.5%0.2% | −0.0*—−0.4% | −0.0—−0.1% | −0.0*−108%−0.0% | 0.0*—0.4% | −0.0*—−0.0% | −0.0—−0.3% | 0.0*—0.4% | |
| Change in cash | 1.8—5.8% | 0.6*—7.6% | −0.7*—−8.3% | 0.4—6.0% | 1.4*+281%18.2% | −0.5*—−6.7% | −0.1*−101%−0.9% | −5.9—−92.1% | 0.4*—4.6% | −13*—−208% | 5.7*—73.0% | −2.2—−25.0% | −17*—−155% | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
What Bionano Genomics, Inc. sells: revenue by product line, fiscal 2025#
As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2024. Lines can overlap (a total and its parts), so they are not added up.
Products and services
- Product revenue(total)$27 M94%-1.0%
- Consumables$14 M49%+9.4%
- Software$6 M22%+3.6%
- Instruments$6 M22%-21%
- Service and other revenue$2 M6.2%-53%
Business segments
- Reportable$29 M100%-7.4%
Countries and regions
- EMEA$14 M49%-0.8%
- Americas$12 M43%-11%
- Asia Pacific$2 M7.8%-23%
Source: SEC annual report (XBRL data) · as of Dec 31, 2025
Executive pay at Bionano Genomics, Inc.#
From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.
| Fiscal year | CEO total pay | Actually paid | Other executives, average | $100 invested |
|---|---|---|---|---|
| 2025R. Erik Holmlin, Ph.D | $1.1 M | $1.0 M | $756 K | $0 |
| 2024R. Erik Holmlin, Ph.D | $990 K | $535 K | $663 K | $2 |
| 2023R. Erik Holmlin, Ph.D | $1.5 M | −$949 K | $1.0 M | $13 |
Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025
Events at Bionano Genomics, Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.
Directors and officers 3 · Material agreement 4 · Agreement ended 1 · Unregistered share sale 1 · Shareholder rights changed 1 · Bylaws or fiscal year changed 1 · Shareholder vote 5 · Results announced 10
| Filed | What happened | Filing |
|---|---|---|
| Results announced | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Shareholder vote | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Material agreement | 8-K | |
| Results announced | 8-K | |
| Shareholder vote | 8-K/A | |
| Directors and officersShareholder vote | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Material agreement | 8-K | |
| Agreement ended | 8-K | |
| Shareholder rights changedBylaws or fiscal year changed | 8-K | |
| Shareholder vote | 8-K | |
| Results announced | 8-K | |
| Material agreement | 8-K | |
| Material agreementUnregistered share sale | 8-K | |
| Shareholder vote | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Nov 10, 2026
Acquisitions and funding#
5 private funding rounds before listing
Private share sales · funding history
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Jul 2024 | $20 M | Private placement after listing | $10 to $50 million | 2 | options | SEC |
| May 2024 | $20 M | Private placement after listing | $10 to $50 million | 4 | equity, debt | SEC |
| Oct 2023 | $35 M | Private placement after listing | $10 to $50 million | 1 | debt, options | SEC |
| Oct 2021 | $42 M | Private placement after listing | $10 to $50 million | 27 | equity | SEC |
| Mar 2019 | $3 M | Private placement after listing | $2 to $10 million | 3 | equity | SEC |
| Sep 2014 | $68 M | No. 5 | $50 to $250 million | 17 | equity, options | SEC |
| Jun 2014 | $5 M | No. 4 | $2 to $10 million | 5 | debt, options | SEC |
| Sep 2013 | $10 M | No. 3 | $10 to $50 million | 5 | debt, options | SEC |
| Jun 2012 | $12 M | No. 2 | $10 to $50 million | 6 | equity, options | SEC |
| Mar 2011 | $23 M | No. 1 | $10 to $50 million | 9 | equity | SEC |
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
H-1B hiring at Bionano Genomics, Inc.#
1 labor condition applications certified in fiscal 2025 for 1 positions, at a median wage of $95 K a year.
| Job title | Positions | Median wage offered |
|---|---|---|
| Data AnalystBioinformatics Scientists | 1 | $95 K |
Where: Boston, MA 1
| Fiscal year | Certified | Positions | Median wage | Filed |
|---|---|---|---|---|
| FY2025 | 1 | 1 | $95 K | 1 |
| FY2024 | 2 | 2 | $161 K | 2 |
| FY2023 | 2 | 2 | $143 K | 2 |
| FY2022 | 6 | 6 | $107 K | 6 |
| FY2020 | 4 | 4 | $100 K | 4 |
Source: US Department of Labor, LCA disclosure data. An application is not a visa: USCIS decides each petition later, and the yearly lottery limits new H-1B visas. Filed as Bionano Genomics, Inc.
From US state WARN notices and SEC 8-K restructuring filings, newest first.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024 | · | · | 64 | · | · | · | · | · | 84 | · | · | · | 148 |
| 2023 | · | · | · | · | · | · | · | · | · | 66 | · | · | 66 |
| Announced | People | Kind | Where | Source |
|---|---|---|---|---|
| 84 people (45% of workforce) | Restructuring planSEC 8-K | “As part of the Reduction, the Company expects to reduce its overall headcount by approximately 84 employees, which represents approximately 45% of its full-time employees as of Sep…” | Filing | |
| Not stated | Restructuring planSEC 8-K | Company-wide plan | Filing | |
| effective | 64 people | LayoffWARN notice | San Diego, California | Notice list |
| 39% of workforce | Restructuring planSEC 8-K | “As part of the Reduction, the Company expects to reduce its overall headcount by approximately 110 to 125 employees, which represents approximately 34% to 39% of its full-time empl…” | Filing | |
| 66 people (17% of workforce) | Restructuring planSEC 8-K | “As part of the Reduction, the Company expects to reduce its overall headcount by approximately 66 employees, which represents 17% of its full-time employees.” | Filing |
Source: State WARN notices and SEC 8-K item 2.05
How Bionano Genomics, Inc. compares in Diagnostics and Research
- Market cap$17 M · higher than 14% of 110
- Revenue$29 M · higher than 21% of 123
- Net margin-96.8% · higher than 11% of 112
- Revenue growth-7.4% · higher than 19% of 89
- Price / sales0.5× · lower than 94% of 85
- Price / book0.4× · lower than 98% of 84
Peer comparison · Diagnostics and Research
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Bionano Genomics, Inc.🇺🇸 | $17 M | — | -96.8% | -7.4% |
| Thermo Fisher Scientific Inc.🇺🇸 | $253.8 B | 35.9× | 14.9% | +3.9% |
| Danaher Corporation🇺🇸 | $166.7 B | 38.5× | 16.9% | +2.9% |
| WuXi AppTec Co., Ltd.🇨🇳 | $70.4 B | 25.4× | 42.1% | — |
| Natera, Inc.🇺🇸 | $58.7 B | — | -5.7% | +35.9% |
| Siemens Healthineers AG🇩🇪 | $52.8 B | 22.9× | 8.7% | — |
| Lonza Group AG🇨🇭 | $51.9 B | — | -4.2% | — |
| Agilent Technologies, Inc.🇺🇸 | $48.8 B | 33.9× | 19.5% | +6.7% |
| IQVIA Holdings Inc.🇺🇸 | $45.1 B | 32.4× | 8.1% | +5.9% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
Sources and freshness
- Market cap:
- Oct 30, 2026
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Employees:
- As on 2021
- Profile updated:
- Nov 20, 2026
Figures from Market data, SEC filing, value.today research, Wikidata, GLEIF register; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Bionano Genomics, Inc.? Verify and update this profile — free
Show Bionano Genomics, Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.